HOWL supply chain intelligence for Werewolf Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Werewolf Therapeutics, Inc. (HOWL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | 90% | Jazz generally reimbursed us for the cost of such activities. |
| JAZZ | Jazz Pharmaceuticals plc | 90% | Reciprocal relationship from JAZZ graph: Reciprocal relationship from HOWL graph: Jazz generally reimbursed us for the cost of such activities. |
| HARPOON-THERAPEUTICS-INC | HARPOON-THERAPEUTICS-INC | 85% | We have licensed from Harpoon certain patents that are directed to single immunoglobulin variable domains that bind human serum albumin. |
| ASND | Ascendis Pharma A/S | 72% | Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from ASND g… |
| ASND | Ascendis Pharma A/S | 72% | lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cy… |
| BMY | Bristol-Myers Squibb Company | 72% | lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme… |
| BMYMP | Bristol-Myers Squibb Co | 72% | lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant … |
| CELG-RI | CELG-RI | 72% | ization will cease to be renewed. We and our contract manufacturers are subject to significant regulation. The manufacturing facilities on which we rely may not continue to meet regulatory requiremen… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from HOWL graph: ization will cease to be renewed. We and our contract manufacturers are subject to significant regulation. The man… |
| CUE | Cue Biopharma, Inc. | 72% | lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme… |
| CUE | Cue Biopharma, Inc. | 72% | Reciprocal relationship from CUE graph: Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cy… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from MRK graph: Reciprocal relationship from HOWL graph: lines and the superior response obtai… |
| MRK | Merck & Co., Inc. | 72% | lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from HOWL graph: lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant … |
| XLO | Xilio Therapeutics, Inc. | 72% | Reciprocal relationship from XLO graph: ction with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment and substant… |
| XLO | Xilio Therapeutics, Inc. | 72% | lines and the superior response obtained by the INDUKINE molecule format when compared to the dosing of recombinant cytokine. In April 2022, we entered into a global collaboration and license agreeme… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JAZZ-PHARMACEUTICALS-IRELAND-LIMITED | JAZZ-PHARMACEUTICALS-IRELAND-LIMITED | 92% | Pursuant to the Purchase Agreement and related ancillary agreements, in consideration for the Transferred Assets, Jazz paid to the Company upfront consideration of $21.0 million, and has agreed to pa… |
| JAZZ | Jazz Pharmaceuticals plc | 90% | Reciprocal relationship from JAZZ graph: Reciprocal relationship from HOWL graph: Jazz acquired exclusive global development and commercialization rights to WTX-613, which has subsequently been desig… |
| JAZZ | Jazz Pharmaceuticals plc | 90% | Jazz acquired exclusive global development and commercialization rights to WTX-613, which has subsequently been designated JZP898, as well as products containing certain isolated recombinant polypept… |
| ASND | Ascendis Pharma A/S | 72% | dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| ASND | Ascendis Pharma A/S | 72% | Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in co… |
| BMY | Bristol-Myers Squibb Company | 72% | dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from BMY graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from BMY grap… |
| BMYMP | Bristol-Myers Squibb Co | 72% | dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from BMYM… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from … |
| CELG-RI | CELG-RI | 72% | , the court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The… |
| CUE | Cue Biopharma, Inc. | 72% | Reciprocal relationship from CUE graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in con… |
| CUE | Cue Biopharma, Inc. | 72% | dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| MRK | Merck & Co., Inc. | 72% | dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in con… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from MYGN g… |
| MYGN | Myriad Genetics, Inc. | 72% | any jurisdiction that we seek patent protection may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights; and, more generally, may affect the value of… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in c… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| XLO | Xilio Therapeutics, Inc. | 72% | Reciprocal relationship from XLO graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in con… |
| XLO | Xilio Therapeutics, Inc. | 72% | dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| ANKURA-TRUST-COMPANY-LLC | ANKURA-TRUST-COMPANY-LLC | 62% | and 2025 was $0.7 million and $0.2 million, respectively, and primarily consisted of the gains recognized for the change in fair value of the derivative liability associated with the K2HV Loan Agreem… |
| ARE-770-784-790-MEMORIAL-DRIVE-LLC | ARE-770-784-790-MEMORIAL-DRIVE-LLC | 62% | cules, or any future product candidates if we receive marketing approval, including marketing, sales and distribution costs; • the potential emergence of competing therapies and other adverse market … |
| HARPOON-THERAPEUTICS-INC | HARPOON-THERAPEUTICS-INC | 62% | we believe we have sufficient funds for our current or future operating plans. Our future capital requirements, both short-term and long-term, will depend on many factors, including: • the scope, pro… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| HOWL-DEBT | Debt stack $32.1M | 90% | Market cache reports total debt of $32.1M. |
| HOWL-DEBT-10057 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| HOWL-OWNER-RA-CAPITAL-MANAGEMENT-L-P | RA CAPITAL MANAGEMENT, L.P. | 90% | 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 49 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| CUE | Cue Biopharma, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 |